Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript ... submit your question by clicking the Q&A icon at the bottom of the screen. Your question will be read, by our panelists.

The Sanofi Global Health Unit plays an important ... submit your question by clicking the Q&A icon at the bottom of the screen. Your question will be read, by our panelists. Now, we'll take ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

Q4 2024 Earnings Conference Call February 7, 2025 3:00 AM ETCompany ParticipantsNicolas Hieronimus - CEOChristophe Babule ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

J&J, Sanofi Stop E.coli Vaccine Trial Due to Low Effectiveness (Reuters) - Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program ...